

Index

a

acetyl-coenzyme A acetyltransferase (ACAT) 199, 275, 276
 acid lipase deficiency 186
 acid sphingomyelinase (ASM) 187, 188
 active termination program 226
 alkyl-dihydroxyacetonephosphate synthase (AGPS) 275, 278
 Alzheimer's disease (AD) 1, 182, 269, 275, 277–279, 281, 283
 – cholesterol/cholesterol esters 276, 277
 – lipidomics 319
 – lipids implicated in 275
 – phospholipase A2 (PLA2) 278, 279
 – phospholipase C (PLC) 279–281
 – phospholipase D (PLD) 279–281
 – plasmalogen phosphatidylethanolamine (pPE) 277, 278
 – sulfatides 277
 ameliorate degeneration 284. *See also* Parkinson's disease (PD)
 amyloid precursor proteins (APPs) 183, 275, 276, 278
 anabolic hormone insulin 177, 178
 analytical lipid outputs 2
 – hierarchical categorization 2, 3
 – lipid class 3, 4
 – molecular lipids 5, 6
 – structurally defined molecular lipids 6, 7
 – sum compositions 4, 5
 animal models, of atherosclerotic research 259, 260
 anionic lipids 54
 anti-inflammatory lipid mediators 188
 apoB-containing lipoproteins 205
 apoC-III-enriched LDL 210
 apoE-containing HDLs 200
 apolipoprotein 180, 181, 198, 199
 apolipoprotein (APOE) e4 allele 276

arachidonic acid (AA) 41, 182, 203, 219, 220, 235, 256, 257, 278, 280
 2-arachidonoyl-glycerol (2-AG) 287
 astrocytes 276, 308–311
 atherogenesis, molecular lipids 252
 atherosclerotic plaque 252, 255, 256
 ATP-binding cassette transporter (ABC) 199
 automated BUME extraction 40
 autophagy 183–186, 270

b

beta-amyloid peptides (A β) 270
 beta-amyloid plaques 275
 beta-amyloid precursor protein (β APP) 279
 bioactive acidic phospholipids 240, 241
 bioinformatics 11, 16, 46, 47, 253, 298, 303
 biomarkers
 – diagnostic, of atherosclerosis 260, 261
 – discovery, strategy 321–326
 – for pharmaceutical research 320, 321
 bis(monoacylglycerol)phosphate 22
 brain lipids 270–272
 – distribution 272
 – mass spectrometry 272–274
 – molecular structures 271
 brutto lipids 4, 7

c

Caenorhabditis elegans 36
 cancer 184–186
 cardiolipin (CL) 22, 40, 54, 55, 202, 203, 272, 298, 299, 300, 301, 303, 307, 308
 – abnormalities, factors associated with 307
 – influence of *in vitro* growth environment 307–311
 – electron transport chain enzyme activities 309
 – distribution of molecular species in mitochondria 304, 308

- electron transport chain
 - abnormalities 299–307
 - interaction with protein amino acid sequence 301
 - relationship of abnormalities with electron transport chain activities 306
 - structure 300
 - cardiovascular disorders (CVDs) 179–181
 - C24–C26 carbon ceramides 9
 - cell adhesion 1, 252
 - β -cell dysfunction 178
 - cell membranes 1, 21, 26, 198, 270, 277, 319
 - cellular lipid distribution 22, 23
 - central nervous system (CNS) 271, 277
 - ceramide (Cer) 25, 204, 210, 272
 - synthesis 178
 - cerebrosides 283
 - CFTR protein 187
 - cholesterol 1, 22, 24, 25, 40, 197–199, 210, 254, 271, 276
 - metabolism 183
 - cholesterol/phospholipid ratio 298
 - cholesteryl ester (CE) 4, 40, 44, 205, 210, 261, 276
 - in dyslipidemia 210
 - in normolipidemic subjects 205
 - cholesteryl ester transfer protein (CETP) 200, 202, 205, 276
 - choline 36, 54, 220
 - chylomicrons 198, 200
 - coenzyme Q 284, 285
 - collision-induced dissociation (CID) 6, 43, 54, 87, 100, 109, 116, 134, 222
 - complex lipids 186
 - coronary artery disease (CAD) 7, 251
 - Crabtree effect 310
 - cyclooxygenase (COX) 219–222, 227, 228, 229, 257
 - inhibitors 321
 - isomers 182, 221
 - cystic fibrosis 187, 188, 206
 - cytochrome P450 monooxygenase (CYP) 219
- d**
- DAG signaling 281
 - Danielli–Davson unit model 21
 - data processing 158–165. *See also* lipidomic data processing
 - biological networks 46
 - de novo lipid identification 159–161
 - and evaluation 46, 47
 - lipidomic data
 - normalization 162–165
 - targeted export 161, 162
 - multivariate approaches 46
 - software 46
 - steps, in data processing workflow 46
 - delta-9 desaturase 14
 - diabetes 177–179
 - diacylglycerides 201, 205
 - diacylglycerol (DAG) 36, 37, 54, 55, 99, 112, 150, 244, 261, 279
 - dihydrosphingomyelin (dhSM) 24, 29
 - 1,3-diphosphatidyl-*sn*-glycerol 299
 - docosahexaenoic acid (DHA) 10, 24, 110, 111, 221, 229, 235, 278
 - dopamine transporter (DAT) 284
 - double bond position 108–110
 - targeted fragmentation 115–123
 - untargeted fragmentation 110–115
 - double bond stereochemistry 104, 105, 123, 124
 - dyslipidemia 175, 177, 206–212
- e**
- eicosapentaenoic acid (EPA) 221, 235
 - electron transport chain (ETC)
 - activities 303
 - proteins 297
 - electrospray ionization (ESI) 53, 73, 85, 100, 222, 223, 235, 274
 - elovl-5 14
 - endocannabinoids 285–287
 - endocytosis 22
 - endolysosomal system 186
 - endoplasmic reticulum (ER) 1, 22, 175
 - lipid composition 22
 - endosomes 25
 - eosinophil-derived lipid mediators 230
 - ependymoblastoma (EPEN) 302
 - epidemic sores 176
 - epoxyeicosatetraenoic acids (EpETE) 221
 - epoxyeicosatrienoic acids (EET) 220
 - epoxy-fatty acids 222
 - ER–PM circuit 22
 - esterification 101
 - ethanolamine 36
 - ethylenediaminetetraacetic acid (EDTA) 14
- f**
- Farber's disease 186, 187
 - fatty acid-binding protein 4 (FABP4)
 - inhibition 261
 - fatty acid-derived fragment ions 161
 - fatty acids 6, 25, 101, 234
 - esterification 101

- position of double bond 102, 103
- survey 236
- fatty acyl-CoA 36
- fatty acids (FAs) 36, 37, 176, 178, 179, 185
- Folch protocol 39, 41, 273
- FPLC-isolated lipoprotein 206
- fragmentation-based lipidomic methods 158
- freeze–thaw cycles 14
- function prediction algorithms 169

g

- β-galactosidase 187
- α-galactosidase-A deficiency 186
- galactosylceramide (GalCer) 24, 25, 29, 36, 61, 74, 76, 78, 82, 85, 93, 259, 271, 272
- gangliosides 9, 29, 37, 79, 178, 187, 204, 244, 245, 258, 272, 283
- Gaucher's disease 186
- glucocerebrosidase gene (GBA) 283
- glucosylceramide (GluCer) 25, 36, 61, 271, 272, 283, 284
- glycerol 5, 24, 25, 36, 122, 158, 198, 240, 299
- glycerolipids (GLs) 36, 37, 44, 101, 150, 175, 178
- glycerophospholipids (GPLs) 22, 24, 36, 37, 44, 54, 100, 101, 113, 148, 149, 150, 244, 269, 271, 272
- glycosphingolipids (GSLs) 24, 25, 186, 211, 244, 258
- functional implications 26–29
- Golgi apparatus 22, 24, 25
- G-protein-coupled S1P receptors 204

h

- hepatic lipase (HL) 199
- hereditary sensory neuropathy 181, 182
- hexosylceramide (HexCer) 25
- high-density lipoprotein cholesterol (HDL-C) 251
- high-density lipoprotein (HDL) 177, 198, 200
- high-throughput drug screening (HTS) 320
- HMG-CoA reductase 277
- homogenization 39, 273
- hydroeicosatetraenoic acids (HETE) 220
- hydroxydocosahexaenoic acids (HDoHE) 222
- hydroxyeicosapentaenoic acids (HEPE) 221
- hydroxy-fatty acids 222–224, 226, 227
- 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductases 321
- hypercholesterolemia 180, 257, 260, 276
- hypertriglyceridemia 7

i

- immune cells 251
- immune system 182
- inflammatory diseases 319
- inositol 36, 220, 241, 271
- isobaric ions 157
- isomeric lipids 103
- isoprostane-containing PC 203, 208, 209

k

- keratinocytes 25, 28, 29
- Kruskal-Wallis test 166

l

- laser microdissection (LMD) 245
- LCAT-mediated cholesterol esterification 209
- LC-ESI-MS/MS-based lipidomics 222
- LC-MS/MS analysis 223, 226
- LC retention times 224, 225
- multiple reaction monitoring (MRM) 224, 225
- sample preparation 222, 223
- standard curves for hydroxy-fatty acids 226
- LDL-C in atherosclerotic lesions 252
- lecithin: cholesterol acyltransferase (LCAT) 199
- leukotrienes (LIs) 219
- lipid
- alterations in 207
- analysis 38
- and atherosclerotic vascular disease 253, 254
- bilayer 21
- classes 3, 7, 37, 101, 150, 198
- derived anti-inflammatory molecules 188
- distribution
- – in mitochondrial membranes 299
- – by nonvesicular routes 23, 24
- diversity 35, 36
- homeostasis 169
- information 7–9
- metabolic disorders 234, 235
- metabolism 169, 269
- – and neurodegenerative diseases 269
- – in yeast 10
- molecular species 233
- – tissue-specific localization 245
- nomenclature 148–151
- peroxidation process 184
- species, complexity and annotation 149
- structure 100
- – database 1

- transfer proteins 183, 208
- lipid–lipid–protein interactions 30
- lipid mass spectrometric data
 - basic properties 147, 151–158
 - deisotoping 154–158
 - isotope pattern for negatively charged 156
 - isotopes 154–158
 - correction 154–158
 - probability for a (lipid) molecule 155
 - mass accuracy, and reproducibility 154
 - mass spectrum 152–154
- lipid mediators 230
 - formation 235
 - leukotrienes (LTs) 219, 235
 - lipoxins (LX) 219
 - prostaglandins (PGs) 219, 235
 - protectins 219
 - resolvins 219
- Lipid Navigator 238
- lipidomes 148, 158, 167, 169, 197, 206, 253, 297, 298, 313, 326
 - of eukaryotic cells 1
 - plasma lipidome characterization 48
 - quantitative monitoring 164, 165
- lipidomic abnormalities, in tumor mitochondria 298
- lipidomic data integration 168, 169
- lipidomic data mining, and visualization 165–168
 - comparative lipidomics 165, 166
 - in biomarker research 166–168
 - multivariate data analysis 166
 - principal component analysis 167
- lipidomic data processing 147, 158–165, 236
 - *de novo* lipid identification 159–161
 - lipidomic data
 - normalization 162–165
 - targeted export 161, 162
 - Lipid Search, application and identification results 237, 238
 - schematic outline 148, 159
 - spectral data quality control 162, 163
 - strategy of lipid search 236, 237
- lipidomics approaches
 - sphingolipid profiling 243
 - TG profiling 242
- lipidomics in efficacy, and safety measurements 261, 262
- lipidomic software tools 158
- lipidomic workflow 47, 48
- lipidoses 186
- lipid rafts 1, 9, 183, 244, 245, 257
- lipid analysis
 - as markers of metabolic syndrome 239–245
 - bioactive acidic phospholipids 240, 241
 - lipid molecular species in specific tissue domains 245
 - oxidative triglycerides 241–244
 - oxidized phospholipids 239, 240
 - sphingolipids 244, 245
- Lipid Search 236–238
- lipids in human diseases 175–189
 - anti-inflammatory lipid mediators 188
 - cancers 184–186
 - cardiovascular disorders 179–181
 - cystic fibrosis 187, 188
 - diabetes 177–179
 - dyslipidemia 177
 - hereditary sensory neuropathy 181, 182
 - lysosomal lipid storage disorders 186, 187
 - neurodegeneration 182–184
 - obesity 176, 177
- LipidView 161, 162
- LipidXplorer 159
- lipoid inclusion 276
- lipoprotein lipase (LPL) 198
 - action 199
- lipoproteomics 200–206
 - altered, in dyslipidemia 206–211
- lipoproteins 254, 255
 - alterations in lipids 207
 - biomarkers 211
 - function 206
 - lipid classes 198
 - lipid composition 197
 - metabolism 198–200
 - plasma 204
 - role 197
 - sterols 205
- lipotoxic metabolite 179
- lipoxygenases (LOX) 219, 221
- low-density lipoprotein (LDL) 7, 177, 180, 186, 198, 199, 202, 204, 205, 209–211, 257
- low-density lipoprotein cholesterol (LDL-C) 251, 270
 - atherosclerotic lesions 252
- lyso-lipids 39
- lysophosphatidic acid (LPA) 12, 99, 240, 241
 - biological activities 240
 - roles in 240
- lysophosphatidylcholine (LPC) 40, 41, 165, 167, 199, 201, 202, 207, 208, 280
- lysophospholipids (LPLs) 58, 79, 112, 198, 199, 209, 234, 274, 278
- lysosomal storage disorder 184, 186, 187

lysosomes 22, 25, 184, 186
lysosphingolipids 204, 209

m

- mass accuracy 154
- mass reproducibility 154
- mass resolution 153
- mass spectrometry in lipidomics 235, 236
 - infusion analysis
 - with precursor ion and neutral loss scanning 236
 - LC-MS and LC-MS/MS analyses 235, 236
 - lipid mediators by LC-MS/MS
 - on triple-stage quadrupole mass spectrometers 236
 - targeted analysis by multiple reaction monitoring for oxidized lipids 236
- MasterScan database 159
- matrix-assisted laser desorption ionization-(MALDI) mass spectrometry 100
 - averaged spectrum 130
 - data processing 139–141
 - instrumentation 134–139
 - ion formation 136, 137
 - lasers and rastering 134–136
 - mass analyzers, and ion detection 137–139
 - major steps 129
 - matrix 131
 - compounds 133, 134
 - techniques for application 131, 133
 - sample preparation 130, 131
- MDMS-based shotgun lipidomics 53, 54
 - 2D mass spectrometry, identification of lipid molecular species 59
 - anionic lipids 59
 - charge neutral but polar lipids 59
 - lipid species 59, 61
 - sphingolipids 59, 61
 - weakly anionic lipids 59
 - intrasource separation 54, 55
 - quantification of lipid molecular species 61
 - PEX7 mouse brain lipidome 63–66
 - principle of quantification 62
 - using a two-step procedure 62, 63
 - workflow 53
- mediator lipidomics, in inflammation and resolution 226–230
 - LC-MS/MS based mediator lipidomics 229
 - MRM chromatograms for hydroxy-fatty acids 227
 - temporal profile of lipid mediators 228
- membrane trafficking 1
- metformin 177
- methyl-*tert*-butyl ether (MTBE) 39
- minor lipids 205, 206, 211
 - in dyslipidemia 211
 - ganglioside GM1 211
 - nonesterified fatty acids 211
 - oxidized lipids 211
 - in normolipidemic subjects 205, 206
- mitochondrial lipidome, alterations in
 - bioinformatic methods interpretation 311–313
 - comparison of CL FA compositions 313
 - IID model 311, 312
 - process controls CL remodeling 311
 - statistical inference methods 311
- mitochondrial membranes
 - fluidity properties 298
 - lipid composition 297
 - lipid distribution, topology of 299
- mitochondrial phospholipids 298
- molecular fragmentation query language 159
- molecular lipidomics
 - advantages 253
 - approaches, clinical diagnostics 11–14
 - limitations 14–16
- molecular lipids 5, 6
 - cholesterol 257, 258
 - eicosanoids 256, 257
 - function of 38
 - phospholipids 258
 - pivotal role in atherogenesis 252
 - sphingolipids 257
- monoacylglyceride 205
- monoacylglycerol (MAG) 22, 36, 37, 55
- monocyte chemotactic protein-1 (MCP-1) 180
- monocyte-derived foam cells 180
- mouse white adipose tissue (WAT) 242
- multidimensional mass spectrometry (MDMS)
 - principle of 55–57
 - variables in 57–59
 - under collision conditions 58
 - in fragment monitoring by tandem MS scans 57
 - under ionization conditions 57, 58
 - related to infusion conditions 57
 - related to sample preparations 58
- multiple reaction monitoring (MRM) 42, 161, 322
 - transitions 224, 225
- mutated trinucleotide expansion of the HTT gene (mHTT) 270
- mutation, on SPTLC1 activity 181
- myelin membranes 24

n

- neuroblastoma (NB) 185
- neurodegenerative diseases 182–184, 269
 - brain lipids 270–272
 - Parkinson's disease 281–287
- neurofibrillary tangles (NFT) 270, 275
- neutral loss scanning (NLS) 42, 236
- Niemann–Pick disease 186
- Niemann–Pick disease type B (NPD B) 206
- nigrostriatum pathway 281, 286, 287
- nitric oxide deficiency 180
- nonalcoholic fatty liver disease (NAFLD) 184, 206
- nonalcoholic steatohepatitis (NASH) 184, 206

o

- obesity 176
 - adipose stores affecting tissue function 176, 177
- Odland bodies 24
- oligodendrocytes 24
- omega-3 docosahexaenoic acid (22:6) (DHA) 24
- omega-3 fatty acid precursors 188
- omega-6/omega-3 ratio 13, 14
- online lipid database 150
- orbitrap 41, 42
- oxfenicine 179
- oxidative phosphorylation (OxPhos) 297
- oxidative stress 176, 179, 183, 184, 208, 233, 239, 275, 278, 282, 283
- oxidative triglycerides 241–244
 - mouse white adipose tissue, application for 242–244
- oxidized lipids 211, 234, 236, 319
- oxidized PC analyses 240
- oxidized phospholipids 239, 240
- OxPhos 309
- oxygen transfer mechanism 9
- ozone-induced dissociation 150, 234

p

- palmitate effect 179
- palmitoyl-oleoyl-phosphatidylglycerol (POPG) 188
- 1-palmitoyl-2-oleoyl-*sn*-glycero-3-phosphocholine 148
- Parkinson's disease (PD) 182, 183, 270, 281–287
 - cerebrosides 283, 284
 - clinical features of 281
 - coenzyme Q 284, 285

- endocannabinoids 285–287
- gene and locus, linked to 282
- lipids/ameliorate degeneration 284
- lipids exacerbating 284
- mitochondrial redox states, modulation 285
- multifactorial disease 281
- phosphatidic acid (PA) 150, 203
- phosphatidylcholine (PC) 2, 40, 148, 202, 206, 207, 234, 271, 323
- phosphatidylethanolamine (PE) 40, 150, 203, 208, 262, 271
- phosphatidylethanolamine-*N*-methyltransferase (PEMT) 10
- phosphatidylglycerol (PG) 9, 38, 203
- phosphatidylinositol (PI) 22, 150, 202, 203, 208, 272
- phosphatidylinositol-4,5-bisphosphate (PIP2) 281
- phosphatidylserine (PS) 150, 203, 272
- phosphoinositide 3-kinase 185
- phosphoinositides 22, 79, 241, 272
- phospholipases 104, 220, 252, 278–281
- phospholipid (PL) 1, 24, 99, 120, 202, 203, 204, 206–209, 261, 300
 - pools 182
- phospholipid transfer protein (PLTP) 199
- PI3K/Akt pathway 279
- plasma lipidomics 2D map 324
- plasmalogen phosphatidylethanolamine (pPE) 203, 208, 277
- plasma membrane (PM) 9, 22
- platelet-activating factor (PAF) 202
- proof-of-concept (PoC) markers 321
- polar lipids 40, 54, 55, 62
- polyketides (PK) 36, 37, 73, 100, 150
- polyunsaturated fatty acid (PUFA) 183, 202, 219, 233, 270
- PoM markers 321
- precursor ion scanning (PIS) 42, 157, 236
- prenol lipids (PR) 36, 37
- principal component analysis 166, 167
- principal plasma phospholipid 202
- proof-of-principle (PoP) 321
- prostaglandins (PGs) 186, 219, 220, 235, 321
- protectins 219, 221, 228
- protein kinase C (PKC) 99
- protein-rich lipoproteins 200
- PUFA-derived lipid mediators 219–222
 - docosanoid 221
 - eicosanoid 220, 221
 - hydroxy-fatty acid 221

q

- quadrupole time-of-flight (QTOF) technology 6, 41, 42, 148, 151, 153, 154, 222
- quality control plot 163

r

- reactive oxygen species (ROS) 181
- recombinant DNA technology 21
- resolvins 219
- reverse cholesterol transport (RCT) 200
- robot-assisted extraction 39
 - procedures 41
 - sample preparation and lipid extraction 15
- rotor–stator homogenizer 39

s

- saccharolipids (SL) 36, 37
- Saccharomyces cerevisiae* 169
- saturation index 7
- scavenger receptors A1 (SR-AI) 199
- selected reaction monitoring (SRM)
 - analysis 236, 322
- serine 36
- serine palmitoyltransferase (SPT) 181
- shotgun lipidomics 42–44
 - analytical validation 44, 45
- SM/PC ratio 209
- sn* position 105–108
- soft ionization technology 222
- solid-phase extraction (SPE) protocols 41
- spectral data quality control 162
- sphinganine-1-phosphate 12
- sphingolipid 14
 - metabolite 185
 - precursor 181
- sphingolipidomics, in biology and disease 91
 - LC-MS/MS 91, 92
 - transcriptomic guided tissue imaging mass spectrometry 92, 93
- sphingolipids (SPs) 25, 36, 37, 101, 203, 204, 209, 210, 244, 245, 272
 - analysis via targeted LC-MS/MS 76, 77
 - data analysis 90
 - description and nomenclature 75
 - in dyslipidemia 209, 210
 - extraction protocol 79–81
 - internal standards 77, 78
 - liquid chromatography 81–83
 - Cer, HexCer, LacCer, SM, ST, and Cer1P 84, 85
 - GlcCer and GalCer 85
 - LCBs and Cer1P 83, 84
 - mass spectrometry 85–87

- metabolism, application for 244, 245
- minor 204
- multiple reaction monitoring 88, 89
- in normolipidemic subjects 203, 204
- quality control 90, 91
- standard curves, generation of 89
- sphingolipid–sterol–protein rafts 30
- sphingomyelin (SM) 24, 25, 151, 183, 187, 201, 204, 206, 209, 234, 272
- sphingomyelinase (SMase) 206
- sphingosine kinase (SphK2), 185
- sphingosine 1-phosphate 12, 178, 185, 204
- Spo14 regulatory factor 1 (Srf1) 281
- statin-induced muscle toxicity 262
- sterol lipids (STs) 36, 37
- sterols 22, 101, 205
- structure-specific fragment ions 159
- substantia nigra pars compacta (SNpc) 183
- subthalamic nucleus (STN) 287
- sum compositions 4, 5
- surfactants 25
- synaptic defects 270
- synaptojanin 1 (SYNJ1) 279

t

- Tay–Sachs disease 187
- 2-tetradecylglycidic acid 179
- thrombogenic collagenous matrix 180
- thromboxanes (TX) 220
- tissue homogenization 39
- toll-like receptor 4-TRIF 239
- total lipid extraction 39
- transmembrane domain (TMD) 11
- triacylglycerides 54, 201, 205, 210
- triacylglycerols (TAGs) 7, 36, 37, 60, 101, 106, 110, 120, 148, 149, 197, 258, 323
- triglycerides 38, 180, 184, 204
- triple quadrupole (QQQ) approaches 41, 43, 45, 86, 87, 322, 323
- tumor mitochondria, lipidomic abnormalities 297, 298
- tumor-promoting molecule 185

u

- uncoupling proteins (UCPs) 285
- user-specified *m/z* tolerance window 159

v

- vaccenic acid 212
- vascular endothelial growth factor (VEGF) 185
- very low-density lipoprotein (VLDL) 38, 108, 177, 198, 201, 203, 205, 212

W

Warburg theory 297, 305, 309
 weakly anionic lipids 55
 Wilcoxon Rank-Sum Test 166
 Wolman's disease 186

X

X-linked lipid storage disease 186

Z

zymosan-induced peritonitis 227, 228